

Financial news for VBLT dated on 2020-06-04: VBL Presents New Data On Potential Of Novel Anti-MOSPD2 Monoclonal Antibodies For Rheumatoid Arthritis At EULAR 2020 Congress

Financial news for VBLT dated on 2020-06-01: Vascular Biogenics F-1 Filing Shows Registration For ~11.49M Share Stock Offering Via Selling Shareholders

Financial news for VBLT dated on 2020-06-01: VBL Presents Interim Data From OVAL Phase 3 Pivotal Study In Ovarian Cancer At ASCO20 Annual Meeting, Showing 58% Or Higher Objective Response Rate

Financial news for VBLT dated on 2020-06-01: VBL Presents Interim Data From OVAL Phase 3 Pivotal Study In Ovarian Cancer At ASCO20 Annual Meeting, Showing 58% Or Higher Objective Response Rate

Financial news for VBLT dated on 2020-05-14: Recap: Vascular Biogenics Q1 Earnings

Financial news for VBLT dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for VBLT dated on 2020-05-14: Vascular Biogenics Q1 EPS \$(0.150) Beats \$(0.170) Estimate, Sales \$366.000K Beat \$160.000K Estimate

Financial news for VBLT dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for VBLT dated on 2020-05-07: The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetrphase Pharma, Dexcom To Join S&P 500

Financial news for VBLT dated on 2020-05-06: VBL Presents New Data On MOSPD2 Antibodies As Potential Treatment For NASH And Colitis At DDW

Financial news for VBLT dated on 2020-04-22: 17 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VBLT dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for VBLT dated on 2020-04-21: VBL Therapeutics Awarded 3.2M NIS Non-Dilutive Grant By The Israel Innovation Authority For VB-111

Financial news for VBLT dated on 2020-04-17: Oppenheimer Maintains Outperform on Vascular Biogenics, Raises Price Target to \$3

Financial news for VBLT dated on 2020-04-06: VBL Therapeutics Says its VB-201 Has Reached a Milestone and the Company Will Receive a Cash Payment at an Undisclosed Amount

Financial news for VBLT dated on 2020-04-02: VBL Therapeutics Reports Its Japanese Licensee NanoCarrier To Extend Ongoing Phase 3 OVAL Trial In Ovarian Cancer

Financial news for VBLT dated on 2020-03-26: VBL Therapeutics Announces Its OVAL Phase 3 Ovarian Cancer Pivotal Study Met The Interim Pre-specified Criterion, Of An Absolute Percentage Advantage Of 10% Or Higher In Ca-125 Response In The Vb-111 Treated Arm Compared To Control

Financial news for VBLT dated on 2020-03-19: Vascular Biogenics: Q4 Earnings Insights

Financial news for VBLT dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for VBLT dated on 2020-03-19: Earnings Scheduled For March 19, 2020

Financial news for VBLT dated on 2020-03-15: The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review

Financial news for VBLT dated on 2020-02-20: VBL Therapeutics Announces The Launch Of A New Clinical Trial Of VB-111 Combined With The Checkpoint Inhibitor, Nivolumab, In Metastatic Colorectal Cancer

Financial news for VBLT dated on 2020-01-08: 50 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for VBLT dated on 2020-01-08: VBL Therapeutics Highlights Publication Of Phase 2 And Phase 3 Data Of VB-111 In Recurrent Glioblastoma Supporting Continued

Development In Investigator-Sponsored Study

Financial news for VBLT dated on 2019-12-11: Vascular Biogenics Granted European Patent Titled Formulations And Dosage Forms Of Oxidized Phospholipids

Financial news for VBLT dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for VBLT dated on 2019-11-14: VBL Therapeutics Q3 EPS \$(0.14), Inline, Sales \$79K Miss \$120K Estimate

Financial news for VBLT dated on 2019-11-10: The Week Ahead In Biotech: Adcom Test For Amarin's Fish Oil Pill, Agile Awaits FDA Verdict

Financial news for VBLT dated on 2019-11-06: VBL Therapeutics Announces New IND For An Investigator-Sponsored Phase 2 Trial Of VB-111 In Recurrent Glioblastoma

Financial news for VBLT dated on 2019-08-13: The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results

Financial news for VBLT dated on 2019-08-13: Vascular Biogenics Q2 EPS \$(0.13), Inline, Sales \$138K Beat \$120K Estimate

Financial news for VBLT dated on 2019-08-11: The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Financial news for VBLT dated on 2019-06-27: Oppenheimer Initiates Coverage On Vascular Biogenics with Outperform Rating, Announces \$2 Price Target

Financial news for VBLT dated on 2019-06-03: VBL Therapeutics Reports Radiographic Analysis of VB-111 Phase 2, 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity

Financial news for VBLT dated on 2019-06-03: VBL Therapeutics Reports Final Phase 1/2 Results Presented At ASCO Showed VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer

Financial news for VBLT dated on 2019-05-15: The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGaA's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

Financial news for VBLT dated on 2019-05-15: Vascular Biogenics Q1 EPS \$(0.12), Inline, Sales \$219K Miss \$1.15M Estimate

Financial news for VBLT dated on 2019-05-11: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for VBLT dated on 2019-04-17: CEO Of VBLT Saying They Are In Talks With Big Pharma About A Possible Deal 'We've Been 'Dancing' With Huge Companies - Soon We'll Be Able To Tell About A Deal'

Financial news for VBLT dated on 2019-03-28: The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO

Financial news for VBLT dated on 2019-03-28: Earnings Scheduled For March 28, 2019

Financial news for VBLT dated on 2019-03-19: 36 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VBLT dated on 2019-03-19: VBL Highlights Presentation Of New Data On Potential Of VB-111 To Stimulate The Immune System And Drive Immune Cells To Infiltrate Tumor Microenvironment

Financial news for VBLT dated on 2019-02-20: VBL Therapeutics Awarded \$2.9M Non-Dilutive Grant By The Israel Innovation Authority

Financial news for VBLT dated on 2019-02-19: VBL Therapeutics Will Present Data On Novel VB-600 Platform At Keystone Conference Feb. 26, 2019

Financial news for VBLT dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for VBLT dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for VBLT dated on 2018-11-29: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018

Financial news for VBLT dated on 2018-11-20: Vascular Biogenics Q3 EPS \$(0.15) Up From \$(0.24) YoY, Sales \$100K Miss \$300K Estimate

Financial news for VBLT dated on 2018-11-19: Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018

Financial news for VBLT dated on 2018-11-16: The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal

Financial news for VBLT dated on 2018-11-16: UPDATE: VBL Therapeutics Says Patients In GLOBE Study 'had relatively high tumor volume, as large-volume tumors were not an exclusion criterion'

Financial news for VBLT dated on 2018-11-16: VBL Therapeutics Reports Results From Phase 3 GLOBE Study In Patients With Recurrent Glioblastoma

Financial news for VBLT dated on 2018-11-15: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018

Financial news for VBLT dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for VBLT dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for VBLT dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio

Financial news for VBLT dated on 2018-10-23: VBL Therapeutics Granted a European Commission Patent for VB-111 Until October 2033

Financial news for VBLT dated on 2018-10-17: The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

Financial news for VBLT dated on 2018-10-16: The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist

Financial news for VBLT dated on 2018-10-15: Benzinga's Top Upgrades, Downgrades For October 15, 2018

Financial news for VBLT dated on 2018-10-15: H.C. Wainwright Upgrades Vascular Biogenics to Buy, Maintains \$3 Price Target

Financial news for VBLT dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for VBLT dated on 2018-08-30: VBL Therapeutics Highlights Publication Of New Data On Lecinnoxoid Drug Candidates For Treatment Of Renal Fibrosis In 'Basic and Clinical Pharmacology and Toxicology'

Financial news for VBLT dated on 2018-08-17: Stocks Which Set New 52-Week Low Yesterday, August 16th

Financial news for VBLT dated on 2018-08-16: The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

Financial news for VBLT dated on 2018-08-16: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for VBLT dated on 2018-08-16: Vascular Biogenics Q2 EPS \$(0.13) Beats \$(0.18) Estimate, Sales \$200K Miss \$300K Estimate

Financial news for VBLT dated on 2018-08-16: Earnings Scheduled For August 16, 2018

Financial news for VBLT dated on 2018-08-12: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Financial news for VBLT dated on 2018-08-09: Stocks Which Set New 52-Week Low Yesterday, August 8th

Financial news for VBLT dated on 2018-08-08: Stocks Which Set New 52-Week Low Yesterday, August 7th

Financial news for VBLT dated on 2018-08-08: The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict

Financial news for VBLT dated on 2018-08-07: Stocks Which Set New 52-Week Low Yesterday, August 6th

Financial news for VBLT dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmmed's Antibiotic Faces FDA Panel

Financial news for VBLT dated on 2018-08-03: Stocks Which Set New 52-Week Low Yesterday, August 2nd

Financial news for VBLT dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for VBLT dated on 2018-07-31: Stocks Which Set New 52-Week Low Yesterday, July 30th

Financial news for VBLT dated on 2018-07-20: Stocks Which Set New 52-Week Low Yesterday

Financial news for VBLT dated on 2018-07-10: Publication By VBL Therapeutics Highlights MOSPD2 As A Potential New Target For Breast Cancer Therapy

Financial news for VBLT dated on 2018-07-03: CVI Investments Reports 5.3% Stake In Vascular Biogenics

Financial news for VBLT dated on 2018-06-27: 54 Biggest Movers From Yesterday

Financial news for VBLT dated on 2018-06-26: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VBLT dated on 2018-06-26: Sabby Reports New 5.31% Stake In Vascular Biogenics

Financial news for VBLT dated on 2018-06-26: VBL Therapeutics Reports \$15.5M Registered Direct Offering Priced At The Market

Financial news for VBLT dated on 2018-06-08: 45 Biggest Movers From Yesterday

Financial news for VBLT dated on 2018-06-07: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for VBLT dated on 2018-06-07: 40 Biggest Movers From Yesterday

Financial news for VBLT dated on 2018-06-06: Mid-Afternoon Market Update: Dow Rises Over 200 Points; Ambarella Shares Slide On Weak Sales Forecast

Financial news for VBLT dated on 2018-06-06: Benzinga Pro's Top 10 Most-Searchd Tickers For Afternoon Of Wed., Jun. 6, 2018

Financial news for VBLT dated on 2018-06-06: 28 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VBLT dated on 2018-06-06: Mid-Day Market Update: Crude Oil Down 1.5%; Axovant Shares Spike Higher

Financial news for VBLT dated on 2018-06-06: Mid-Morning Market Update: Markets Mostly Higher; Signet Jewelers Earnings Top Estimates

Financial news for VBLT dated on 2018-06-06: Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate

Financial news for VBLT dated on 2018-06-06: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VBLT dated on 2018-06-05: 5 Stocks Moving In Tuesday's After-Hours Session

Financial news for VBLT dated on 2018-06-05: VBL Therapeutics Shares Up 34.9% After Co. Announced It Will Present t Data On Novel MOSPD2 Program In Oncology, Inflammation At BIO Convention

Financial news for VBLT dated on 2018-06-05: VBL Therapeutics Reports Will Present Data On Novel MOSPD2 Program In Oncology, Inflammation At BIO Convention; Highlights Data Indicating MOSPD2 Is Required For Directional Movement Of Tumor cells, Certain Immune Cells

Financial news for VBLT dated on 2018-05-18: 24 Stocks Moving In Friday's Pre-Market Session

Financial news for VBLT dated on 2018-05-17: 7 Stocks Moving In Thursday's After-Hours Session

Financial news for VBLT dated on 2018-05-17: Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

Financial news for VBLT dated on 2018-05-17: Vascular Biogenics Q1 EPS \$(0.24) Misses \$(0.20) Estimate, Sales \$163K Beat \$150K Estimate

Financial news for VBLT dated on 2018-05-17: Earnings Scheduled For May 17, 2018

Financial news for VBLT dated on 2018-05-16: B Riley Likes Tocagen On Prospects For Company's Brain Cancer Drug

Financial news for VBLT dated on 2018-05-13: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for VBLT dated on 2018-04-09: VBL Therapeutics Wins a \$2.5M Grant From the Israel Innovation Authority

Financial news for VBLT dated on 2018-03-15: VBL Therapeutics Reports FY17 EPS \$(0.37) vs \$(0.57) Est., Sales \$13.864M vs \$10M Est.

Financial news for VBLT dated on 2018-03-09: Benzinga's Top Upgrades, Downgrades For March 9, 2018

Financial news for VBLT dated on 2018-03-09: Chardan Capital Downgrades Vascular Biogenics to Neutral

Financial news for VBLT dated on 2018-03-09: 56 Biggest Movers From Yesterday

Financial news for VBLT dated on 2018-03-08: Vascular Biogenics Shares Down 63% After Phase 3 GLOBE Study Didn't Meet Primary Endpoint, H.C. Wainwright Downgraded Stock to Neutral

Financial news for VBLT dated on 2018-03-08: Mid-Afternoon Market Update: Dow Turns Lower; Express Scripts Shares Climb On Acquisition News

Financial news for VBLT dated on 2018-03-08: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for VBLT dated on 2018-03-08: Mid-Day Market Update: Comtech Telecomm Rises Following Strong Q2 Results; Vascular Biogenics Shares Fall

Financial news for VBLT dated on 2018-03-08: H.C. Wainwright Downgrades Vascular Biogenics to Neutral

Financial news for VBLT dated on 2018-03-08: Mid-Morning Market Update: Markets Open Higher; American Eagle Posts In-Line Profit

Financial news for VBLT dated on 2018-03-08: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for VBLT dated on 2018-03-08: VBL Therapeutics Phase 3 GLOBE Study Did Not Meet Its Pre-Specified Primary Endpoint Of Overall Survival

Financial news for VBLT dated on 2018-02-08: VBL Therapeutics Receives a Milestone Payment From NanoCarrier, Terms Not Disclosed

Financial news for VBLT dated on 2017-12-27: VBL Therapeutics Announces the First Patient in its Phase 3 Study of VB-111

Financial news for VBLT dated on 2017-12-27: VBL Therapeutics Reports First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Partnership with the GOG Foundation, Inc.

Financial news for VBLT dated on 2017-12-18: Vascular Biogenics F-3 Filing Shows Registration For \$150M Mixed Securities Shelf Offering

Financial news for VBLT dated on 2017-12-18: VBL Therapeutics Says New Biomarker Data Supports Direct Link between VB-111's Dual Mechanism of Action and its Clinical Effect on Overall Survival and Progression Free Survival in Recurrent Glioblastoma Multiforme Patients

Financial news for VBLT dated on 2017-11-20: 45 Biggest Movers From Friday

Financial news for VBLT dated on 2017-11-17: Mid-Afternoon Market Update: Crude Oil Up Over 2%; Foot Locker Shares Rise On Earnings Beat

Financial news for VBLT dated on 2017-11-17: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for VBLT dated on 2017-11-17: Mid-Day Market Update: Abercrombie & Fitch Climbs After Q3 Beat; Century Casinos Shares Drop

Financial news for VBLT dated on 2017-11-17: Mid-Morning Market Update: Markets Open Lower; Foot Locker Tops Q3 Expectations

Financial news for VBLT dated on 2017-11-17: VBL Therapeutics Reports Pricing Of 2.5M Share Common Stock Offering For \$18.75M

Financial news for VBLT dated on 2017-11-17: 31 Stocks Moving In Friday's Pre-Market Session

Financial news for VBLT dated on 2017-11-16: VBL Therapeutics Reports Proposed Public Offering of 2.5M Shares of Ordinary Shares

Financial news for VBLT dated on 2017-11-14: VBL Therapeutics Reports Q3 EPS \$(0.24) vs \$(0.20) Est.

Financial news for VBLT dated on 2017-11-06: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for VBLT dated on 2017-11-06: VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan, VBL To Receive \$15M Upfront And Is Entitled To Receive \$100M In Development And Commercial Milestone Payments

Financial news for VBLT dated on 2017-11-06: UPDATE: VBL Therapeutics to Receive up-front Payment of \$15M, \$100M+ in Development and Commercial Milestone Payments

Financial news for VBLT dated on 2017-11-06: Nanocarrier Signs Exclusive Agreement with VBL Therapeutics for VB-111 in Japan

Financial news for VBLT dated on 2017-10-20: VBL Therapeutics Reports Orphan Drug Designation for VB-111 in Europe

Financial news for VBLT dated on 2017-10-02: UPDATE: VBL Says Topline Data Expected In Q1'18

Financial news for VBLT dated on 2017-10-02: UPDATE: VBL Says DSMC Unanimously Recommended Study Continue As Planned To Completion

Financial news for VBLT dated on 2017-10-02: UPDATE: VBL Says DSMC Confirmed No Added Follow Up Will Be Necessary

Financial news for VBLT dated on 2017-10-02: VBL Therapeutics Reports Outcome In Third, Final DSMC Review Of Phase 3 GLOBE Trial Of VB-111 In Recurrent GBM: Safety Concerns Were Not Identified

Financial news for VBLT dated on 2017-10-02: VBL Therapeutics Reports Positive DSMC Recommendation That Supports Safety Of VB-111, Expects Top-Line Data In Q1 2018

Financial news for VBLT dated on 2017-09-26: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VBLT dated on 2017-09-20: 15 Biggest Mid-Day Losers For Wednesday

Financial news for VBLT dated on 2017-08-14: VBL Therapeutics Q2 EPS \$(0.18) vs \$(0.19) Est., No Sales

Financial news for VBLT dated on 2017-08-14: Earnings Scheduled For August 14, 2017

Financial news for VBLT dated on 2017-06-19: VBL Therapeutics Offers Long-Term Survival In Phase 2 Trials Of Patients With Multiple Tumor Types

Financial news for VBLT dated on 2017-06-15: VBL Therapeutics Names Corinne Epperly COO

Financial news for VBLT dated on 2017-06-08: VBL Therapeutics Wins \$2.5M Grant

Financial news for VBLT dated on 2017-06-05: Vascular Biogenics Gives Update on Phase 2 Trial

Financial news for VBLT dated on 2017-05-15: VBL Therapeutics Q1 EPS \$(0.19) vs \$(0.16) Est, No Sales

Financial news for VBLT dated on 2017-05-11: VBL Therapeutics Shows Data on VB-111 in Combination with Checkpoint Inhibitor at the 20th Annual ASGCT Meeting

Financial news for VBLT dated on 2017-04-20: VBL Therapeutics +.70 After-Hours @\$5.90 After Co Reports Positive DSMC Review In Phase 3 GLOBE Trial Of VB-111

Financial news for VBLT dated on 2017-04-20: VBL Therapeutics Reports Positive DSMC Review In Phase 3 GLOBE Trial Of VB-111

Financial news for VBLT dated on 2017-04-03: H.C. Wainwright Holding NASH Investor Conference Today; Attendees Include Allergan, Enanta Pharma, Madrigal Pharma, Vascular Biogenics, Albireo Pharma, CymaBay, Gemphire Therapeutics, And Galectin Therapeutics

Financial news for VBLT dated on 2017-03-28: H.C. Wainwright Reiterates Buy On Vascular Biogenics Ltd., Maintains \$11 Price Target

Financial news for VBLT dated on 2017-03-27: VBL Therapeutics FY 2016 EPS \$(0.64) vs \$(0.66) Est, No Sales

Financial news for VBLT dated on 2017-03-27: Earnings Scheduled For March 27, 2017

Financial news for VBLT dated on 2017-03-23: 15 Biggest Mid-Day Gainers For Thursday

Financial news for VBLT dated on 2017-02-21: VBL Tehrapeutics Phase 2 Study Of VB-111 Met Primary Endpoint Of 6-Month Progression Free Survival

Financial news for VBLT dated on 2017-01-06: VBL Therapeutics Completes Enrollment in the Pivotal GLOBE Study

Financial news for VBLT dated on 2016-12-05: VBL Therapeutics Reports Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM

Financial news for VBLT dated on 2016-11-29: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for VBLT dated on 2016-11-29: Roth Capital Out Positive On Vascular Biogenics, Expects Large Pharma Partnership Based On Ovarian Cancer Program, Reiterates \$17 PT and Buy Rating

Financial news for VBLT dated on 2016-11-29: CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

Financial news for VBLT dated on 2016-11-29: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VBLT dated on 2016-11-29: VBL Therapeutics Says VB-111 Met Primary Endpoint, Shows Evidence Of Overall Survival Benefit

Financial news for VBLT dated on 2016-11-10: VBL Therapeutics Reports Q3 EPS \$(0.12) vs. Est. \$(0.15)

Financial news for VBLT dated on 2016-10-13: VBL Therapeutics Announces Plans to Establish New Manufacturing Facility For Potential Commercialization Of VB-111

Financial news for VBLT dated on 2016-10-13: 15 Stocks That Rallied For Three Days On No News

Financial news for VBLT dated on 2016-09-07: Vascular Biogenics Pops to High of \$4.31 on Volume

Financial news for VBLT dated on 2016-08-25: Vascular Biogenics Shares Off Highs at \$4.25; Traders Indicating to Stake of Lee Family May Not be New; Filing Contains Information Regarding Collection of Debt from Keffi VI

Financial news for VBLT dated on 2016-08-25: Thai Lee Reports 21.6% Stake in VBLT in 13D

Financial news for VBLT dated on 2016-08-15: VBL Therapeutics Q2 EPS (\$0.14) vs (\$0.23) est, No Revenue

Financial news for VBLT dated on 2016-08-15: VBL Therapeutics Reports Q2 EPS \$(0.14) vs. Est. \$(0.23)

Financial news for VBLT dated on 2016-06-28: H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics

Financial news for VBLT dated on 2016-06-28: The Market In 5 Minutes: Stocks Start To Recover From Brexit Onslaught

Financial news for VBLT dated on 2016-06-17: 15 Stocks Moving In Friday's Pre-Market Session

Financial news for VBLT dated on 2016-06-16: Vascular Biogenics Spikes to High of \$4.60 on Vol

Financial news for VBLT dated on 2016-06-16: Vascular Biogenics Spikes to High of \$4.28 on Vol

Financial news for VBLT dated on 2016-06-10: Vascular Biogenics Spikes to High of \$5.22 on Vol

Financial news for VBLT dated on 2016-06-07: 8 Biggest Mid-Day Losers For Tuesday

Financial news for VBLT dated on 2016-06-07: Vascular Biogenics Jumped 80%, But 'Provocative' OvCa Data Will Provide Further Clinical Validation

Financial news for VBLT dated on 2016-06-07: Mid-Morning Market Update: Markets Mostly Higher; Valeant Earnings Miss Views

Financial news for VBLT dated on 2016-06-07: 12 Stocks Moving In Tuesday's Pre-Market Session

Financial news for VBLT dated on 2016-06-07: Vascular Biogenics Reports \$24M Registered Direct Offering

Financial news for VBLT dated on 2016-06-06: Mid-Afternoon Market Update: Helios and Matheson Analytics Jumps Amid News Of Merger With Zone Technologies; ProNAi Therapeutics Shares Drop

Financial news for VBLT dated on 2016-06-06: Roth Capital Reiterates Buy Rating, \$22 Target on Vascular Biogenics Amid 83% Gain in Stock Today

Financial news for VBLT dated on 2016-06-06: 9 Biggest Mid-Day Gainers For Monday

Financial news for VBLT dated on 2016-06-06: Vascular Biogenics Surges 80% Off Double Catalyst

Financial news for VBLT dated on 2016-06-06: Mid-Day Market Update: Dow Surges Over 100 Points; Adamis Pharmaceuticals Shares Slide

Financial news for VBLT dated on 2016-06-06: Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around \$1 Billion

Financial news for VBLT dated on 2016-06-06: Unconfirmed Chatter That Vascular Biogenics May Be Takeover Candidate For Bristol Myers Squibb

Financial news for VBLT dated on 2016-06-06: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for VBLT dated on 2016-06-06: Pre Market Movers

Financial news for VBLT dated on 2016-06-06: VBL Therapeutics VB-111 Showed Significant Increase In Overall Survival At Therapeutic vs. Low Dose Level, 60% Durable Repsonse Rate; Trial Designed To Evaluate Safety, Tolerability, and Explore Efficacy

Financial news for VBLT dated on 2016-06-03: VBL Therapeutics Spikes to \$6.66 Following VB-111 News

Financial news for VBLT dated on 2016-06-03: VBL Therapeutics Reports Data Presented at ASCO Showed Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 vs Historical Avastin

Financial news for VBLT dated on 2016-05-13: VBL Therapeutics Reports Q1 EPS \$(0.21), Inline

Financial news for VBLT dated on 2016-05-13: Earnings Scheduled For May 13, 2016

Financial news for VBLT dated on 2016-05-03: VBL Therapeutics Announces Clinical Data to be Presented at 2016 ASCO Annual Meeting

Financial news for VBLT dated on 2016-05-03: Vascular Biogenics Spikes to High of \$3.68 on Vol

Financial news for VBLT dated on 2016-04-19: VBL Therapeutics Reports Publication of NASH Data for Lecinnoxoids Molecules VB-201, VB-703

Financial news for VBLT dated on 2016-03-29: VBL Therapeutics Reports FY15 EPS \$(0.73) vs. Prior Year \$(3.09)

Financial news for VBLT dated on 2016-03-29: Earnings Scheduled For March 29, 2016

Financial news for VBLT dated on 2016-02-22: VBL Therapeutics Reports Launch of First

Israeli Site Related to GLOBE Int'l Pivotal Trial for VB-111

Financial news for VBLT dated on 2015-12-01: Newly Granted US Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 Until October 2033

Financial news for VBLT dated on 2015-11-19: VBL Therapeutics Reports Significant Improvement of 12 Month Overall Survival With VB-111 Compared to Pooled Data From Four Avastin Studies at the Annual Meeting of the Society for Neuro-Oncology

Financial news for VBLT dated on 2015-11-12: VBL Therapeutics Reports Q3 EPS \$(0.29) vs. Est. \$(0.19)

Financial news for VBLT dated on 2015-11-09: Benzinga's Top Initiations

Financial news for VBLT dated on 2015-11-09: Piper Jaffray Initiates Coverage on Vascular Biogenics at Overweight

Financial news for VBLT dated on 2015-11-09: Piper Jaffray Initiates Coverage on Vascular Biogenics at Overweight

Financial news for VBLT dated on 2015-11-03: Vascular Biogenics Reports Pricing Of 2.5M Shares At \$6/Share

Financial news for VBLT dated on 2015-10-21: VBL Therapeutics Presents Positive Data on VB-111 in Advanced Radioactive Iodine Refractory Differentiated Thyroid Cancer at the ITC 2015 Conference, Met Primary Endpoint

Financial news for VBLT dated on 2015-09-28: Morning Market Gainers

Financial news for VBLT dated on 2015-09-28: Benzinga's Top #PreMarket Losers

Financial news for VBLT dated on 2015-09-28: VBL Therapeutics Announces Phase 2 Data from Trial of VB-111 in rGBM, Says Met Primary Endpoint of Statistically-Significant Increase in Overall Survival

Financial news for VBLT dated on 2015-09-24: Benzinga's Volume Movers

Financial news for VBLT dated on 2015-09-23: Morning Market Losers

Financial news for VBLT dated on 2015-09-22: A \$6 Stock Hitting \$25? Vascular Biogenics Could, Chardan Says

Financial news for VBLT dated on 2015-09-22: Benzinga's Volume Movers

Financial news for VBLT dated on 2015-09-22: Morning Market Gainers

Financial news for VBLT dated on 2015-09-22: Monday's After-Hours Movers Led By Vascular Biogenics, Ultragenyx And Red Hat

Financial news for VBLT dated on 2015-09-22: Benzinga's Top #PreMarket Gainers

Financial news for VBLT dated on 2015-09-21: Chardan Capital Initiates Coverage on Vascular Biogenics at Buy, Announces \$25.00 PT

Financial news for VBLT dated on 2015-09-18: Morning Market Gainers

Financial news for VBLT dated on 2015-09-17: VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference

Financial news for VBLT dated on 2015-08-20: VBL Therapeutics Reports Initial Patient Dosed in Important Phase 3 Trial of VB-111 in Recurrent Glioblastoma

Financial news for VBLT dated on 2015-08-13: 6-K from Vascular Biogenics Shows Q2 Loss of \$0.15/Share vs Loss of \$0.17/Share Est.

Financial news for VBLT dated on 2015-06-01: 16 Biotech Stocks Moving Off The ASCO Conference

Financial news for VBLT dated on 2015-06-01: Benzinga's Top #PreMarket Gainers

Financial news for VBLT dated on 2015-06-01: Adam Feuerstein @adamfeuerstein Tweet: \$VBLT is not presenting its suspect GBM data at ASCO. Misleading press release.

Financial news for VBLT dated on 2015-06-01: VBL Therapeutics Announces Updated Interim Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma

Financial news for VBLT dated on 2015-06-01: VBL Therapeutics Shares Rise 25%

Premarket Following Presentation of Phase 1/2a Data from VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO

Financial news for VBLT dated on 2015-05-30: VBL Therapeutics to Present Phase 1/2a Data from VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO

Financial news for VBLT dated on 2015-05-22: Roth Capital Initiates Coverage on Vascular Biogenics at Buy, Announces \$13.00 PT

Financial news for VBLT dated on 2015-05-14: Morning Market Gainers

Financial news for VBLT dated on 2015-05-13: VBL Therapeutics Reports Will Present Phase 1/2 Data for VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO

Financial news for VBLT dated on 2015-04-27: Oppenheimer Assumes Vascular Biogenics at Perform

Financial news for VBLT dated on 2015-03-25: Morning Market Gainers

Financial news for VBLT dated on 2015-03-25: Benzinga's Top #PreMarket Gainers

Financial news for VBLT dated on 2015-03-25: US Stock Futures Flat Ahead Of Durable-Goods Orders Data

Financial news for VBLT dated on 2015-03-25: VBL Therapeutics Q4 EPS -\$0.23 vs -\$0.24 est

Financial news for VBLT dated on 2015-03-25: VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma

Financial news for VBLT dated on 2015-03-19: SeaWorld, Mattress Firm Lead Thursday's After-Hours Movers

Financial news for VBLT dated on 2015-02-17: JMP Securities Downgrades Vascular Biogenics to Market Perform

Financial news for VBLT dated on 2015-02-17: Morning Market Losers

Financial news for VBLT dated on 2015-02-17: Benzinga's Top #PreMarket Losers

Financial news for VBLT dated on 2015-02-17: VBL Therapeutics to Discontinue Development of VB-201 in Ulcerative Colitis, Psoriasis Following Phase 2 Results

Financial news for VBLT dated on 2015-02-17: VBL Therapeutics Announces Removal of FDA Partial Clinical Hold on VB-111

Financial news for VBLT dated on 2015-02-06: VBL Therapeutics Receives European Patent Issuance on Lecinnoxoid Platform Technology

Financial news for VBLT dated on 2015-01-22: Deutsche Bank Raises Vascular Biogenics Price Target

Financial news for VBLT dated on 2014-12-22: VBL Therapeutics Announces Positive Phase 2a Data for VB-111 in Recurrent Thyroid Cancer

Financial news for VBLT dated on 2014-12-15: VBL Therapeutics Announces Last Patient Out in Phase 2 Clinical Studies of VB-201 in Psoriasis and Ulcerative Colitis

Financial news for VBLT dated on 2014-11-13: VBL Therapeutics to Present Interim Phase 2 Data From VB-111 In Recurrent Glioblastoma At 19th Annual Scientific Meeting Of The Society For Neuro-Oncology

Financial news for VBLT dated on 2014-11-03: VBL Therapeutics to Present Interim Phase 2 Data From VB-111 in Recurrent Glioblastoma

Financial news for VBLT dated on 2014-10-08: Stocks Hitting 52-Week Highs

Financial news for VBLT dated on 2014-10-01: Shares of Vascular Biogenics Open for Trade at \$6.02, IPO Priced at \$6/Share

Financial news for VBLT dated on 2014-10-01: Expected IPOs For October 1

Financial news for VBLT dated on 2014-09-30: Updated Filing from Vascular Biogenics Shows Co. Expecting to Sell ~6.666M Shares at \$6/Share in IPO